At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 294 enrolled
Drug / intervention
AGN-214868 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study of the Safety and Efficacy of AGN-214868 in Patients With Postherpetic Neuralgia
In Brief
A Phase 2 clinical trial evaluating AGN-214868 and Placebo to AGN-214868 for Neuralgia, Postherpetic. Completed, enrolled 294 participants across 4 sites in 4 countries.
Detailed Summary
This study will evaluate the safety and efficacy of AGN-214868 in patients with postherpetic neuralgia (PHN) - nerve pain.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeuralgia, Postherpetic
CountriesCzechia, Germany, Poland, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2010
Enrollment StartJun 2010
Primary CompletionOct 2011
Study CompletionJan 2012
TodayJul 2026
First PostedMay 24, 2010
Enrollment StartJun 1, 2010
Primary CompletionOct 1, 2011
Study CompletionJan 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 16.1 years ago
Interventions
AGN-214868drug
AGN-214868 injected into areas of postherpetic neuralgia pain for total dose per treatment.
Placebo to AGN-214868drug
Placebo to AGN-214868 injected into areas of postherpetic neuralgia pain per treatment.